LearnGlossaryMarketStocksSuperinvestorsSign in

OCUL

Ocular Therapeutix, Inc.

Healthcare · $2.5B market cap

Verdict

We can't put a fair value on OCUL right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-0.4% a year✗
Sales growth24.4% a year✓
Free cash flow growth—?
Return on invested capital-38.1%✗

Follow OCUL

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Aug 31, 2026: no open-market purchases and 1 sale worth $11K. Why purchases matter

Sales

Notman Donald

Chief Operating Officer · 2026-08-31

Sold

$11K

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works